Current Studies

Read our Testimonials

Enrolling Trials

Clinical trials are at the heart of medical advances. Clinical trials participants enroll to possibly receive the latest treatments for their condition, to receive additional care and attention from our professional staff, and to help find better treatments for future patients. In the United States, clinical trials must meet rigorous standards and be registered and approved by regulatory agencies. Participation is free of charge and transportation can be provided for all trial participants. To learn if you are eligible to participate in our enrolling studies, please contact us at:

Call us at 512-279-1251

Email: Ivana Gunderson

About 10-20% of macular degeneration is classified as the wet form. In this form, there is often a rapid onset of distortion and blurring of the vision in one eye due to leakage or bleeding in the macula. If diagnosed early, currently available drugs are quite effective in maintaining or improving vision when injected into the eye. These treatments are not a cure and must be continued indefinitely to maintain vision. When one eye progresses to the wet form of the disease there is an increased risk of about 10% annually for the other to develop the same condition.  Current research is aimed at reducing the number of treatments and improving vision.

  • Roche BP40923 Bluetail – A Phase 1 open label study investigating new drug, RO7200394, in patients with wet AMD.
  • Boehringer-Ingelheim 1336.0007 – A Phase 1 open label study evaluating BI 836880, a new molecule with a new mechanism of action, in patients with wet AMD.
  • Genentech BP41783 Longitude – A longitudinal study of FDA approved drug Eylea, to explore the relationship between various biomarkers and retinal imaging in patients with wet AMD and diabetic macular edema.
  • Regenexbio RGX-314-2104 Atmosphere -A Phase 2b/3 study evaluating efficacy of a single administration of RGX-314 Gene Therapy compared to standard of care treatment in patients with wet AMD.

Diabetic retinopathy is the leading cause of vision loss in working age Americans. It is a common cause of permanent visual impairment in middle age and is a complication of diabetes. The risk of developing diabetic retinopathy is related to length of diabetes and poor diabetic control. It can be asymptomatic and is most commonly found on a routine retinal exam. Diabetes damages the fragile blood vessels in the retina leading to hemorrhages and leakage. Current treatments can reduce the blood vessel damage when the drugs are injected into the eye. Current research is directed at developing longer lasting drugs and treatments that can decrease the severity of diabetic retinopathy to prevent significant complications.

  • Roche BP41321 Canberra – A Phase 2, placebo-controlled study, evaluating an oral agent in patients with diabetic retinopathy with or without diabetic macular edema. Learn More
  • Regenexbio RGX-314-2202 Altitude: A Phase 2 study assessing a novel treatment approach with RGX-314 Gene Therapy delivered via a single in office injection in participants with diabetic retinopathy.
  • Ocuphire OPI-APXDR-201 ZETA-1 -A Phase 2, placebo-controlled study, evaluating an oral administration of APX3330 in patients with diabetic retinopathy.

Diabetic patients can have chronic leakage of blood vessels that can lead to diabetic macular edema, or swelling of the retina. This is the leading cause of vision loss from diabetic retinopathy. It causes a progressive blurring of the vision that is not correctable with glasses. This can be successfully treated with current drugs about 60% of the time. Current drugs are injected into the eye on a monthly basis as needed. It is commonly in both eyes, but may not affect both eyes at the same time. Current research is directed at developing more effective and longer lasting treatments.

  • Novartis LKA651x2202 – A Phase 2, multiple dose study of a new molecule, LKA651, administered alone or in combination with standard of care treatment in patients with diabetic macular edema.
  • Roche BP40899 Dovetail – A Phase 1 open-label study evaluating a new drug, RO7200220, administered alone or in combination with standard of care treatment in patients with diabetic macular edema or uveitic macular edema.
  • Oxurion THR-149-002 – A phase 2 study evaluating a new treatment approach with drug THR-149 compared to standard of care treatment in patients with diabetic macular edema.
  • Genentech BP41783 Longitude – A longitudinal study of FDA approved drug Eylea, to explore the relationship between various biomarkers and retinal imaging in patients with wet AMD and diabetic macular edema.

Most macular degeneration is classified as the dry form. This label means that there is no associated bleeding or leakage in the macula. The main symptoms are blurred vision or blind spots in the vision. These symptoms are slowly progressive and can ultimately lead to legal blindness. There is currently no FDA approved treatment for this condition. Current research is focused on slowing or stopping the progression of the disease and vision loss.

  • Genentech GR40973 Gallegos – A Phase 2, placebo-controlled study, assessing intravitreal injections of FHTR2163 in patients with geography atrophy due to dry age-related macular degeneration (dry AMD). Upon completion of parent study, patients will have the option to participate in a secondary open-label study where all patients will get active treatment.
  • Ionis 696844-CS5 – A Phase 2, placebo-controlled study evaluating multiple doses of IONIS-FB-LRX administered subcutaneously in patients with geography atrophy due to dry age-related macular degeneration (dry AMD).
  • Annexon Biosciences ANX007-GA-01 – A Phase 2, placebo-controlled study evaluating intravitreal injections of ANX007 in patients with geographic atrophy due to dry age-related macular degeneration (dry AMD).
  • Alexion ALXN2040-GA-201 – A Phase 2, placebo-controlled study of an oral agent, Danicopan, in patients with geographic atrophy secondary to dry age-related macular degeneration (dry AMD).

Macular telangiectasia type 2 is a rare congenital retinal disease that usually manifests itself in young adults or middle age. It can lead to blurred vision in one or both eyes. There is currently no FDA approved treatment for this condition. We are enrolling patients in a nationwide registry study that will help gather data on this rare condition that may help with future clinical trials and development of treatments. Participating in the registry consists of a one-time in office visit that is of no cost to the patient and benefits include: confirmation of diagnosis by an independent central reader, and to stay informed about future interventional clinical trials.

  • Mactel NHOR– A natural history, observation, and registry study of macular telangiectasia type 2.

Retinal vein occlusions are the third most common retinal disease leading to loss of vision. They are associated with aging of the blood vessels. This can be exacerbated by hypertension and diabetes. Glaucoma is also a risk factor. Current treatments are successful in improving vision about 75% of the time. The treatments include drugs that are injected into the eye and laser surgery. Current research is directed at developing more effective and longer lasting drugs.

  • Genentech GR41986 Comino – A Phase 3 study evaluating safety and efficacy of intravitreal injections of faricimab compared to Eylea in patients with macular edema secondary to Central Retinal Vein Occlusion.
  • Genentech GR41984 Balaton – A Phase 3 study evaluating safety and efficacy of intravitreal injections of faricimab compared to Eylea in patients with macular edema secondary to Branch Retinal Vein Occlusion.
  • AimMax CPN-301 – A Phase 3, double-masked study evaluating efficacy of APP13007, a topical solution, for treatment of inflammation and pain after cataract surgery.
  • Roche BP40899 Dovetail – A Phase 1 open-label study evaluating a new drug, RO7200220, administered alone or in combination with standard of care treatment in patients with diabetic macular edema or uveitic macular edema.

  • Check back for soon for upcoming trials.

Closed Trials

The trials below are trials we have participated in, the investigational data has been collected by the pharmaceutical companies sponsoring the trials, and those companies have moved the drugs to the next stage of development for the particular medication in question. These trials do not have any active participants. We maintain an updated list of these trials for educational and academic purposes.

  • Abbott: M327 – A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis.
  • Abbott: M877 – A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate, Posterior, or Pan-uveitis.
  • Abbott: M880 – A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate,Posterior, or Pan-uveitis.
  • Aciont, Inc.  DSPV-201 –  A randomized, parallel group, double-masked, active-controlled Phase1/2 clinical trial to evaluate the efficacy and safety of dexamethasone sodium phosphate Visulex system for the treatment of non-infectious anterior uveitis.
  • Acucela: 4429-201 – Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy.
  • Acuity: (CARE) – A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the treatment of Subfoveal Choroidal Neovascularization associated with Wet Age-Related Macular Degeneration.
  • Aerpio: A Phase 2, Randomzied, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy of Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema.
  • Alcon: C-10-034 – A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis.
  • Alcon: C-04-18 – Clinical Evaluation of the Safety of Next Generation Ophthalmic Irrigation Solution Compared to BSS PLUS® for Use During Surgery for Removal of Epimacular Membrane and Vitrectomy.
  • Alcon: C-09-067 (Race) – Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD.
  • Alcon (C13001): A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration.
  • Alcon (OWL) – ESBA1008 Microvolume Study.
  • Alimera: C0105001 (FAME)- Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema.
  • Allergan: 206207-008 (RVO) – Dexamethasone PS DDS versus Placebo in a 3-year study for treatment of Retinal Vein Occlusions.
  • Allergan: 206207-011 – A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema.
  • Allergan (REACH): Multiple Dose of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-Related Macular Degeneration.
  • AMPIO Pharmaceuticals (Optina): A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adult Patients With Diabetic Macular Edema.
  • Athenagen: ATG003-201 – Mecamylamine HCL ophthalmic solution versus placebo in the treatment of Neovascular Age Related Macular Degeneration (wet).
  • Athenagen: ATG003-203 – Safety and Efficacy of ATG003 in Patients with AMD Receiving Anti-VEGF.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol A – A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol B – Intravitreal triamcinolone acetonide versus laser in the treatment of Diabetic Macular Edema.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol D – Post-vitrectomy long-term assessment.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol H – Assessment of Avastin for the treatment of Diabetic Macular Edema.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol I – Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol J – Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol M- Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol N- An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol O – Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol P – A Pilot Study in Individuals with Center-Involved DME Undergoing Cataract Surgery.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol Q – An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery.
  • Diabetic Retinopathy Clinical Research (DRCR): Protocol T: A comparative study of intravitreal aflibercept, bevacizumab, and ranibizumab for diabetic macular edema.
  • Endo Pharmaceuticals: EN3324-201 – Efficacy and Safety of EN3324 in Subjects With Chronic Low Back Pain (CLBP).
  • Eyetech: EOP1023 (LEVEL) – Macugen maintenance therapy in Macular Degeneration.
  • Genaera: MSI-1256-301 – A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal CNV associated with Age-Related Macular Degeneration.
  • Genentech: FVF2587g (ANCHOR) – Phase III research trial evaluating Rhu Fav v2 vs. Visudyne therapy in Classic Subfoveal Macular Degeneration.
  • Genentech: FVF4165g (BRAVO) – A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.
  • Genentech: FVF4166g (CRUISE) – A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion.
  • Genentech: FVF4170g (RISE) – A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus.
  • Genentech: CFD4870g (MAHALO)- Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy.
  • Genentech: FVF3426g (HORIZON) – Lucentis Treatment of CNV in Wet Age Related Macular Degeneration.
  • Genentech: FVF3426g (HORIZON) – Extension to BRAVO and CRUISE; the use of Lucentis in patients with macular edema secondary to branch and central retinal vein occlusion.
  • Genentech: FVF3869g (SAILOR) – Evaluating the Safety and Tolerability of Ranibizumab (Lucentis) in Naïve and Previously Treated Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
  • GlaxoSmithKline (BAM114311) – A Phase 2 Study to Investigate GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
  • GlaxoSmithKline: MD7108240 – A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD.
  • GlaxoSmithKline: OUTCOME – PRACTICE Study: Study Manual and Chart Abstraction.
  • GlaxoSmithKline: FFR110537 – A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis.
  • GlaxoSmithKline: MD7114987 – To Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients with Neovascular Age Related Macular Degeneration.
  • Grunenthal: KF0151Y/10 – NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain.
  • iCO Therapeutics and Juvenile Diabetes Foundation (iDEAL Study): A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of FoveAL Center.
  • Iveric Bio ISEE2008 – A phase III, sham-controlled study to assess the safety and efficacy of intravitreal injections of Zimura (Complement 5 inhibitor) in patients with Geographic Atrophy.
  • LPath LT1009-Oph-002 (PEDigree) – Phase 1B Multi-Center Blinded and Randomized Study of iSONEP Administered as Intravitreous Injections to Subjects with PED Secondary to Exudative Age-Related Macular Degeneration.
  • Lpath (Nexus): A Phase IIA study of iSONEP as monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for treatment of patients with choroidal neovascularization secondary to age-related macular degeneration.
  • LuxBiosciences: LX21101, LX21102, LX21103 (LUMINATE) – The assessment of LX211 in the treatment of active and quiescent anterior, posterior, intermediate, and pan non-infectious uveitis.
  • LUX 211-11– A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis.
  • Macusight: DR-002 (DIAMOND) – Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema.
  • Macusight: AMD-003 (EMERALD) – Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration.
  • Molecular Partners: MP0112-CP02 – Study of MP0112 Intravitreal Injection in Patients with Diabetic Macula Edema.
  • NGM Biopharmaceutiucals NGM621-GA-201 – A phase II, sham-controlled study to evaluate the safety and efficacy of intravitreal injections of NGM621 in subjects with Geographic Atrophy
  • NeoVista: NVI-114 (CABERNET) – A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration.
  • Novartis: CAEB071A2211 – Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis.
  • Novartis: CBPD952A2308 (DENALI) – Lucentis monotherapy versus Lucentis + Visudyne in the treatment of naïve patients with Neovascular Age Related Macular Degeneration (wet).
  • Novartis: CBPD952E2202 (VERITAS) – Laser with Visudyne plus triamcinolone acetonide versus Visudyne plus Macugen in patient with Subfoveal Chorodial Neovascularization secondary to Age Related Macular Degeneration (wet).
  • Novartis: CBPD952E2201 (VisTA) – A Randomized Trial to evaluate the effect of photodynamic therepy using Visudyne in combination with intravitreal injection of Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Choroidal Neovascularization secondary to Age-Related Macular Degeneration.
  • Novartis CCLG561-2201 – A proof-of-concept study of  intravitreal CLG561 as a monotherapy or in combination with LFG316 in subjects with geographic atrophy secondary to ARMD.
  • Novartis Raptor – A Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion.
  • Novartis Raven – A Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion.
  • Ophthotech (Fovista): A Phase 3 Randomized, Double-Masked, Controlled Trial to establish the safety and efficacy of intravitreous administration of FOVISTA(TM) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
  • OPKO: ACU-301 (COBALT) – Intravitreal bevasiranib administered every 8 or 12 weeks as maintenance following Lucentis versus Lucentis monotherapy every 4 weeks.
  • Pfizer: A3921034 – A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects with Dry Eye.
  • Pfizer: B0451001 (MONET)- Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing An Investigational Drug PF-04523655 Versus Lucentis In The Treatment Of Subjects With Choroidal Neovascularization.
  • Pfizer: B1181002- Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy.
  • Pfizer (B1181003) – A Phase II Study evaluating dosages of RN6G in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
  • Pfizer (B1261009): A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema.
  • Quark (Matisse): An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema
  • Regeneron: VGFT-OD-0706 Da Vinci- An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration.
  • Regeneron: VGFT-OD-0603 (Clear-IT 1b) – Repeated doses of intravitreal administration of two VEGF Trap Formulations in subjects with Neovascular Age Related Macular Degeneration (wet).
  • Regeneron Pharmaceuticals: VGFT-OD-0605 (VIEW 1) – Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD).
  • Regeneron Pharmaceuticals: VGFT-OD-0702 – Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD.
  • SCORE – The Standard Care vs. Corticosteroid (triamcinolone acetonide) for Retinal Vein Occlusion.
  • Stealth SPIAM-202 – A Phase 2 study evaluating safety and efficacy of subcutaneous injections of Elamipretide in patients with geographic atrophy.
  • Thrombogenics: TG-MV-007 (MIVI) – Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion.
  • Thrombogenics– (TG-MV-014): A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole.

Retina Research Center

Phone Icon
512-279-1251
Fax: 512-600-2882

Our Location

9707 Anderson Mill Rd # 100,
Austin, TX 78750